Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes

NCT01615978 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and tolerability of the medication liraglutide in Japanese adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 15 people

Who can join Ages 20–64 · all sexes

Timeline Started 2003-12 · est. completion 2004-03

Where 1 site · Japan

What this study is testing ClinicalTrials.gov NCT01615978 ↗

Description as written by the study sponsor.

This trial is conducted in Japan. The aim of this trial is to assess the safety after multiple s.c. (subcutaneously) doses of liraglutide in Japanese subjects with type 2 diabetes.

Treatments tested

liraglutide Drug

5 mcg/kg daily for 14 days. Injected subcutaneously once daily
liraglutide Drug

Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
placebo Drug

Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1

Main thing measured	24-hour profiles of serum calcitonin
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01615978 ↗